Infinity Pharmaceuticals

Infinity Pharmaceuticals is engaged in the discovery and development of drugs for the treatment of cancer and related diseases in the United States. Its leading product candidates include IPI-504 (Retaspimycin Hydrochloride), an intravenously administered small molecule inhibitor of Heat Shock Protein 90 (Hsp90). Infinity is advancing eganelisib, a first-in-class, orally administered immuno-oncology development candidate that selectively inhibits PI3K-γ in multiple clinical studies.